Javelin Pharmaceuticals has announced the preliminary results of a randomized, placebo- controlled pilot Phase II study with intranasal Ketamine in 60 patients with moderate-to-severe pain following
bunion surgery.
Treatment with intranasal Ketamine was well-tolerated. There were no unexpected or serious adverse events related to the study drug. Local adverse events associated with nasal administration (throat irritation, oral discomfort, oral hypoaesthesia, rhinorrhea) were more common in the intranasal
Ketamine treatment groups. General adverse events that were reported more frequently for the active drug treatment group included dizziness, dysgeusia and somnolence.
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Matrix Surgical’s OmniPore Implants Cleared for Marketing
The company expects to launch additional variants in early 2019.
AbbVie, Novartis Reach Deal on Humira Biosimilar
AbbVie reported Humira sales of $18.4 billion in 2017.